This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia (VV/IC)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Bruce Kahn, Scripps Health Identifier:
First received: January 11, 2010
Last updated: May 12, 2014
Last verified: May 2014
In order to investigate whether the pain in women with vulvodynia may represent bladder origin pain, we will be performing a diagnostic test for interstitial cystitis (IC) in women with generalized vulvodynia. Those women with a positive test for IC, we will be performing a series of bladder treatments (instillations) for IC and checking symptoms throughout the trial to see if significant relief of vulvar pain can be obtained through treatment for IC.

Condition Intervention Phase
Vulvodynia Drug: Bladder instillation with heparin/ lidocaine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

Resource links provided by NLM:

Further study details as provided by Bruce Kahn, Scripps Health:

Primary Outcome Measures:
  • Reduction in pelvic pain / vulvodynia [ Time Frame: 16 weeks ]

Enrollment: 0
Study Start Date: December 2012
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Drug: Bladder instillation with heparin/ lidocaine
9 bladder instillations in 6 weeks

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • We plan to enroll women 18 years or older with GV and negative tests for urine infection, negative cultures for Chlamydia and gonorrhea when indicated, and negative screens or cultures for yeast infection or bacterial vaginosis when indicated.
  • Patient symptoms will need to include no or minimal vaginal discharge.
  • Patients will have a minimum Visual Analog Score for vulvar pain of at least 3/10.
  • In order to receive bladder instillations, patients will need to have a positive potassium sensitivity test.

Exclusion Criteria:

  • We will exclude patients from enrollment if they use chronic narcotic pain medication or have localized vulvodynia. (We believe that localize vulvodynia is less likely of bladder origin).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01048177

United States, California
Scripps Clinic
San Diego, California, United States, 92130
Sponsors and Collaborators
Scripps Health
Principal Investigator: Bruce Kahn, M.D. Scripps Clinic
  More Information

Responsible Party: Bruce Kahn, MD, Scripps Health Identifier: NCT01048177     History of Changes
Other Study ID Numbers: IRB-09-5381
Study First Received: January 11, 2010
Last Updated: May 12, 2014

Keywords provided by Bruce Kahn, Scripps Health:
interstitial cystitis
pelvic pain

Additional relevant MeSH terms:
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases
Vulvar Diseases
Genital Diseases, Female
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents processed this record on September 21, 2017